Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Whither hope for pharmacological treatment of Charcot-Marie-Tooth disease type 1A?

Patel PI, Pleasure D.

JAMA Neurol. 2013 Aug;70(8):969-71. doi: 10.1001/jamaneurol.2013.3285. No abstract available.

PMID:
23797977
2.

High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial.

Lewis RA, McDermott MP, Herrmann DN, Hoke A, Clawson LL, Siskind C, Feely SM, Miller LJ, Barohn RJ, Smith P, Luebbe E, Wu X, Shy ME; Muscle Study Group.

JAMA Neurol. 2013 Aug;70(8):981-7. doi: 10.1001/jamaneurol.2013.3178.

3.

Charcot-Marie-Tooth disease type 1A: is ascorbic acid effective?

Pareyson D, Solari A.

Lancet Neurol. 2009 Dec;8(12):1075-7. doi: 10.1016/S1474-4422(09)70270-4. Epub 2009 Oct 7. No abstract available.

PMID:
19818689
4.

Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease.

Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Fontés M.

Nat Med. 2004 Apr;10(4):396-401. Epub 2004 Mar 21.

PMID:
15034573
5.

Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial.

Micallef J, Attarian S, Dubourg O, Gonnaud PM, Hogrel JY, Stojkovic T, Bernard R, Jouve E, Pitel S, Vacherot F, Remec JF, Jomir L, Azabou E, Al-Moussawi M, Lefebvre MN, Attolini L, Yaici S, Tanesse D, Fontes M, Pouget J, Blin O.

Lancet Neurol. 2009 Dec;8(12):1103-10. doi: 10.1016/S1474-4422(09)70260-1. Epub 2009 Oct 7.

PMID:
19818690
6.

[Ascorbic acid: a first generation drug for Charcot-Marie-Tooth disease].

Fontès M.

Med Sci (Paris). 2004 Oct;20(10):843-4. French. No abstract available.

7.

136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A)8-10 April 2005, Naarden, The Netherlands.

Reilly MM, de Jonghe P, Pareyson D.

Neuromuscul Disord. 2006 Jun;16(6):396-402. Epub 2006 May 8. No abstract available.

PMID:
16684603
8.

Extended treatment of childhood Charcot-Marie-Tooth disease with high-dose ascorbic acid.

Burns J, Ouvrier RA, Yiu EM, Ryan MM.

J Peripher Nerv Syst. 2011 Sep;16(3):272-4. doi: 10.1111/j.1529-8027.2011.00348.x. No abstract available.

PMID:
22003943
9.

[Ascorbic Acid and Charcot-Marie-Tooth Disease].

Noto Y.

Brain Nerve. 2015 Oct;67(10):1241-6. doi: 10.11477/mf.1416200289. Review. Japanese.

PMID:
26450076
10.

Ascorbic acid for treatment of CMT1A: the jury is still out.

Shy M.

Lancet Neurol. 2009 Jun;8(6):505-7. doi: 10.1016/S1474-4422(09)70112-7. Epub 2009 May 6. No abstract available.

PMID:
19427270
11.

Poor tolerability of high dose ascorbic acid in a population of genetically confirmed adult Charcot-Marie-Tooth 1A patients.

Toth C.

Acta Neurol Scand. 2009 Aug;120(2):134-8. doi: 10.1111/j.1600-0404.2008.01134.x. Epub 2008 Dec 22.

PMID:
19154534
12.

Quality of life in children with CMT type 1A.

Ramchandren S, Shy ME, Finkel RS.

Lancet Neurol. 2009 Oct;8(10):880-1; author reply 881. doi: 10.1016/S1474-4422(09)70247-9. No abstract available.

PMID:
19747650
13.

Ascorbic acid for treatment in CMT1A: what's next?

de Visser M, Verhamme C.

Lancet Neurol. 2011 Apr;10(4):291-3. doi: 10.1016/S1474-4422(11)70042-4. No abstract available.

PMID:
21393064
14.

A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27].

Pareyson D, Schenone A, Fabrizi GM, Santoro L, Padua L, Quattrone A, Vita G, Gemignani F, Visioli F, Solari A; CMT-TRIAAL Group.

Pharmacol Res. 2006 Dec;54(6):436-41. Epub 2006 Sep 9.

PMID:
17029975
16.

A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients.

Fledrich R, Schlotter-Weigel B, Schnizer TJ, Wichert SP, Stassart RM, Meyer zu Hörste G, Klink A, Weiss BG, Haag U, Walter MC, Rautenstrauss B, Paulus W, Rossner MJ, Sereda MW.

Brain. 2012 Jan;135(Pt 1):72-87. doi: 10.1093/brain/awr322. Epub 2011 Dec 20.

PMID:
22189569
17.

Factors associated with foot and ankle strength in healthy preschool-age children and age-matched cases of Charcot-Marie-Tooth disease type 1A.

Rose KJ, Burns J, North KN.

J Child Neurol. 2010 Apr;25(4):463-8. doi: 10.1177/0883073809340698. Epub 2009 Aug 11.

PMID:
19671887
18.

Charcot-Marie-Tooth disease type 1A presenting as calf hypertrophy and muscle cramps.

Krampitz DE, Wolfe GI, Fleckenstein JL, Barohn RJ.

Neurology. 1998 Nov;51(5):1508-9. No abstract available.

PMID:
9818900
19.

Elevated expression of messenger RNA for peripheral myelin protein 22 in biopsied peripheral nerves of patients with Charcot-Marie-Tooth disease type 1A.

Yoshikawa H, Nishimura T, Nakatsuji Y, Fujimura H, Himoro M, Hayasaka K, Sakoda S, Yanagihara T.

Ann Neurol. 1994 Apr;35(4):445-50.

PMID:
7512319
20.

Utility of Charcot-Marie-Tooth Neuropathy Score in children with type 1A disease.

Haberlová J, Seeman P.

Pediatr Neurol. 2010 Dec;43(6):407-10. doi: 10.1016/j.pediatrneurol.2010.06.004.

PMID:
21093731

Supplemental Content

Support Center